• English

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.

    For immediate release:

    April 24, 2021


    Media contacts:

    Deidre McCabe, Director of Communications, 410-767-3536
    Charles Gischlar, Deputy Director, Media Relations, 410-767-6491  ​

    Maryland Department of Health Statement on the Reintroduction of Johnson & Johnson’s Janssen COVID-19 Vaccine

    The U.S. Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) have lifted the pause on the use of the Johnson & Johnson (Janssen) COVID-19 vaccine. The decision is based on the CDC’s Advisory Committee on Immunization Practices (ACIP) recommendation that health care providers resume the use of the Johnson & Johnson vaccine for adults aged 18 and above.

    The CDC and FDA issued the following statement:

    Following a thorough safety review, including two meetings of the CDC’s Advisory Committee on Immunization Practices, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention have determined that the recommended pause regarding the use of the Johnson & Johnson (Janssen) COVID-19 Vaccine in the U.S. should be lifted and use of the vaccine should resume.

    Based on ACIP’s recommendations, the Maryland Department of Health (MDH) supports the reintroduction of the Johnson & Johnson vaccine. Maryland COVID-19 vaccine providers may resume using their available supplies of the Johnson & Johnson vaccine.

    “The Johnson & Johnson vaccine is one of our most important tools in the ongoing fight to prevent hospitalizations and deaths associated with COVID-19,” said Dr. Jinlene Chan, MDH’s deputy secretary for public health services. “By resuming use of this safe and effective vaccine in Maryland, we will continue to bolster our ability to stay ahead of new cases and emerging variants.”

    As part of this reintroduction, providers should share with patients updated information about the potential risks related to the vaccine, including the rare occurrence of thrombosis with thrombocytopenia syndrome (TTS), a condition where a rare type of blood clot is found in combination with low platelet levels.

    Federal agencies carefully reviewed reported events of TTS in patients who received the Johnson & Johnson COVID-19 vaccine. Out of nearly 8 million doses of the Johnson & Johnson COVID-19 vaccine administered, 15 cases of TTS have been identified. Most such cases occurred in females ages 18 through 49 years, with the onset of symptoms one to two weeks after vaccination. Three cases have resulted in fatalities. 

    MDH believes that, while it is important to understand the risks of any medical therapy, the benefits of COVID-19 vaccines outweigh the risks of TTS. Providers should carefully review the following information from CDC and FDA:

    MDH will follow up with additional guidance and information for clinicians. 



    The Maryland Department of Health is dedicated to protecting and improving the health and safety of all Marylanders through disease prevention, access to care, quality management and community engagement. 


    Follow us on Twitter @MDHealthDept and at Facebook.com/MDHealthDept.